Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has been given a $8.00 target price by Maxim Group in a report released on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective points to a potential upside of 94.65% from the stock’s current price.
Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at 4.11 on Wednesday. The company’s 50 day moving average price is $4.05 and its 200 day moving average price is $3.00. The stock’s market capitalization is $76.80 million. Brainstorm Cell Therapeutics has a 52-week low of $2.06 and a 52-week high of $5.10.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Thursday, March 30th. The biotechnology company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04. On average, equities research analysts anticipate that Brainstorm Cell Therapeutics will post ($1.14) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Brainstorm Cell Therapeutics Inc (BCLI) Given a $8.00 Price Target by Maxim Group Analysts” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at http://www.wkrb13.com/markets/2066261/brainstorm-cell-therapeutics-inc-bcli-given-a-8-00-price-target-by-maxim-group-analysts.html.
A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Perceptive Advisors LLC bought a new position in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 400,000 shares of the biotechnology company’s stock, valued at approximately $1,016,000. Perceptive Advisors LLC owned 2.14% of Brainstorm Cell Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.22% of the company’s stock.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2066261/brainstorm-cell-therapeutics-inc-bcli-given-a-8-00-price-target-by-maxim-group-analysts.html
Receive News & Ratings for Brainstorm Cell Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.